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MicroRNAs control cellular processes by regulating expression of their tar-
get genes. Here we report that neuro-epithelial transforming gene 1
(NET1) is a target of tumor suppressor microRNA 22 (miR-22). miR-22 is
downregulated in peripheral blood mononuclear cells derived from chronic
myeloid leukemia (CML) patients and in CML cell line K562. NET1 was
identified as one of the targets of miR-22 using both in vitro and in vivo
experiments. Either mutations or naturally occurring single-nucleotide
polymorphisms in NET1 30-UTR that map at the miR-22 binding site were
found to affect binding of miR-22 to NET1 mRNA. Over expression of
NET1 in K562 cells resulted in increased proliferation. However decreased
proliferation and alteration in cell cycle were observed on either overex-
pression of miR-22 or knockdown of NET1 expression respectively. We
also found that overexpression of miR-22 or NET1 knockdown inhibits
actin fiber formation, probably by downregulation of NET1 as NET1
knockdown also resulted in depletion of actin fiber formation. We suggest
that the oncogenic properties of CML cells are probably due to deregulat-
ed expression of NET1 as a result of altered expression of miR-22.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs
that have emerged as important regulatory factors
involved in cellular decision making processes (for a
recent review see [1]). They provide an additional layer
of control at the post-transcriptional level and have
been shown to be involved directly or indirectly in
almost all physiological processes, most notably
development, immune response and oncogenesis [2,3].
Mostly, miRNAs exert their regulatory effect by
targeting cognate mRNAs through specific interaction
with 30-UTRs. Despite our understanding about some
of the rules that govern miRNA–mRNA interaction,
the problem of computational prediction of miRNA
targets has not been completely solved. Available tools
for target prediction display high levels of false
positives and experimental validation is required for
identification of targets. Since the biological basis of
miRNA function is through modulation of targets, it
is important to identify targets for functional charac-
terization of miRNAs.
Chronic myelogenous leukemia (CML) is a myelo-
proliferative disorder of white blood cells characterized
Abbreviations
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by the presence of Philadelphia chromosome that is a
result of a translocation event between the 9th and
22nd chromosomes [4]. The role of miRNAs in initia-
tion, progression or treatment response of CML is not
clear and there are only a few studies that link
miRNAs with CML. miR-15 has been shown to regu-
late expression of c-MYB, thereby altering the prolifer-
ative properties of CD34+ hematopoietic cells of
CML patients [5]. miR-10a has also been implicated in
CML as it is downregulated and its target upstream
stimulatory factor 2 showed inverse expression with
respect to miRNA level [6]. In the chronic phase, miR-
17-92 cluster is upregulated. The expression of the
cluster decreased with imatinib treatment similar to
that seen after knockdown of BCR-ABL kinase gene
[7]. On the other hand, miR-203 has been found to be
a tumor suppressor as there was a reduction in both
ABL/BCR-ABL level and proliferation of cells on its
overexpression in CML cell line K562 [8]. miR-29b
has also been shown to suppress CML cell prolifera-
tion [9]. Many miRNAs have been implicated in differ-
ent types of cancers. However, their role in CML has
not been studied. We carried out miRNA profiling of
normal peripheral blood mononuclear cells (PBMCs),
K562 and HL60 cells [10]. Our results suggested a gen-
eralized defect in miRNA production in K562 cells
resulting in reduced levels of a number of miRNAs
including miR-22. We observed downregulation of
DICER1 in K562 cells [10]. Downregulation of
DICER1 may be one of the reasons for reduction in
miRNA level. miR-22 is thought to be a differentia-
tion specific miRNA [11]. It is an important regulator
of cardiac hypertrophy [12]. It is downregulated in gas-
tric cancer and thought to be involved in invasion and
migration [13]. A high miR-22 level is also known to
suppress colon, ovarian and lung cancer progression
and hypoxia signaling in colon cancer cells [14–17]. All
these studies strongly indicate that miR-22 is a tumor
suppressor, but its precise role and the mechanisms
involved have not been addressed so far.
In the present study we have explored the role of
miR-22 in CML and have identified one of the major
targets of this miRNA. Our observations suggest a
correlation between miR-22 level and the oncogenic
status of cells. miR-22 is significantly downregulated in
cells from CML patients, K562 and HL60 cells. We
identified and validated NET1, a RhoA specific guan-
ine nucleotide exchange factor, as one of the targets of
miR-22. We also show that miR-22 has growth regula-
tory properties as it decreases proliferation of K562/
HL60 cells, and this effect is mediated through NET1.
It appears from our results that miR-22 participates in
cancer cell biology by regulating NET1 expression.
Results
We had shown before that levels of a number miR-
NAs were considerably lower in a CML cell line K562
compared with normal PBMCs [10]. This may be an
inherent property of CML cells or could be due to
specific changes in K562 cells during the process of
adaptation to become a cell line. If the former possibil-
ity is true then some of these miRNAs may have an
important role in tumor formation. We have analyzed
cells from CML patients and the results are shown
below. It is also known that CML cells undergo
differentiation to megakaryocytes in the presence of
phorbol 12-myristate 13-acetate (PMA) [18]. The
induced differentiated cells are thought to be a good
model for normal cells and the dynamics of molecular
changes can be studied easily using molecular tools in
this system. Therefore, we have also used PMA-treated
K562 cells in our attempt to understand the role of
downregulation of miR-22 in CML.
miR-22 is downregulated in chronic myeloid
leukemia cells
We estimated levels of a few selected miRNAs in
PBMCs from CML patients and compared them with
those of normal individuals. Initially qRT-PCR was
used to quantify the levels of three miRNAs (miR-22,
miR-27a and miR-324-5p) that displayed a low level of
expression in K562 cells (Fig. 1A). These miRNAs are
reported to have altered expression in several other
malignancies, but so far there is no report that shows
their involvement in CML [19–21]. The qRT-PCR
results showed that the levels of miR-27a and
miR-324-5p were also low in patients compared with
normal individuals. However, the decrease was not as
much as that seen for miR-22, being on average 80%,
44% and 51% for miR-22, miR-27a and miR-324-5p
respectively (patient subset 1–5) (Fig. 1A). Therefore,
further experiments were carried out only with respect
to miR-22. In order to validate these results, we esti-
mated the expression level of miR-22 in PBMCs of 25
more CML patients (patient subset 6–30). The results
showed a consistent decrease in its expression ranging
from 59% to 95% (on average 80% decrease)
(Fig. 1B). Then we compared the expression of miR-22
in K562 relative to that in normal PBMCs. No signifi-
cant amount of miR-22 was observed in K562 cells as
expected, although PBMCs displayed a significant level
of miR-22 (Fig. 1C). PBMCs are a mixed population
of lymphoid and myeloid lineage cells where myeloid
cells constitute approximately 50–85% of the total
PBMCs [22]. In order to quantitate miR-22 expression
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level in myeloid cells we further enriched the myeloid
population by magnetic separation using IgG1 CD33
antibody conjugated with magnetic micro-beads. The
CD33 cell surface marker is expressed on myeloid
lineage cells but not on lymphoid cells [23]. We con-
firmed the purity of the separated myeloid cells by
staining them with another myeloid specific marker
CD13 [23]. The flow cytometry of CD13 stained cells
suggested 98% final enrichment of myeloid cells
(Fig. 1D). miR-22 expression was observed mainly in
normal CD33+ cells but not in CD33+ cells from
patient PBMCs suggesting that downregulation of
miR-22 is a characteristic feature of leukemic myeloid
cells (Fig. 1E).
A number of studies have shown that K562 can dif-
ferentiate into megakaryocytes after treatment with
PMA [18]. In order to check if miR-22 levels would
also change on PMA treatment, northern blot analysis
was carried out (Fig. 1F). The level of miR-22
increased by 85% upon PMA treatment while there
was no change in the level of RNU6B RNA suggesting
that miR-22 level is dependent on the differentiation
status of cells.
NET1 is one of the targets of miR-22
miRNAs control cellular processes by binding and
then regulating the levels and translation of their
A D
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Fig. 1. miR-22 is downregulated in CML patients. Total RNA was extracted from indicated cells (PBMCs from CML patients, K562 cell line
and PBMCs from normal individuals) following the standard protocol for analyzing miR-22 expression level. U6 RNA was used as a control.
(A) Real-time PCR of miR-22, miR-27a and miR-324-5p (patient subset 1–5). (B) Real-time PCR of miR-22 in another set of patient samples
(patient subset 6–30). (C) Northern blot of miR-22 of PBMCs/K562 cells using anti-miR-22 probe. (D) Flow cytometric analysis of enriched
CD33+ cells using IgG CD33 antibody coated magnetic beads. Analysis suggested 98% enrichment of CD33+ cells. (E) qRT-PCR of miR-22 in
CD33+ enriched myeloid cells. (F) Northern blot of miR-22 after treatment of K562 cells with 20 nM PMA. miR-22 antisense DNA
oligonucleotide was used as a probe for hybridization. Graphical data points denote mean  SD (t test, *P ≤ 0.05, ***P ≤ 0.001).
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target mRNAs [1]. In general there is a reciprocal rela-
tionship of miRNA levels with those of cognate
mRNAs and the encoded polypeptides [1]. Usually
miRNA targets can be predicted using a number of
bioinformatics tools (for a recent review see [24]). It is
recognized that target prediction tools quite often yield
many false positive targets; therefore it is important
that predictions are validated using experiments. Our
prediction strategy involved integrating a web based
target prediction program (MIRECORDS) and gene
expression data from microarrays as described in
Materials and methods. We found seven putative
targets of miR-22 using the pipeline described here
(Fig. 2A). A list of predicted targets is shown in
Table 1. These putative targets were further substanti-
ated by determining the expression of target genes and
A
B
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Fig. 2. Identification of miR-22 targets. (A) Targets of miR-22 were predicted using intersection of the online tool MIRECORDS and genes
upregulated in K562 cells as identified by microarray experiments. The predicted targets are shown in Table 1. (B) qRT-PCR of indicated
genes that were selected from Table 1. Data are represented as fold change in expression of K562 cells in comparison with normal
PBMCs. (C) Expression level of some of the target genes after overexpression of miR-22. The controls were scrambled RNA expressing
cells. (D) Gene function network for NET1 was generated by the online tool CONCEPTGEN. (E) qRT-PCR of NET1 in PBMCs of CML patients
(patient subset 14–30). Graphical data points denote mean  SD (t test, ***P ≤ 0.001).
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that of miRNAs. Levels of many predicted target
genes, such as NET1, YARS and IPO7, displayed
inverse correlation with that of miR-22 in normal
PBMCs and K562 cells by real-time PCR (Fig. 2B).
All putative targets showed a high level of expression
in K562. In order to further confirm, miR-22 was
overexpressed and the expression levels of different
putative targets were determined. We expected that, on
miR-22 overexpression, levels of real target genes
would go down. The results showed that the levels of
only two putative targets (NET1 and IPO7) were
reduced significantly (Fig. 2C). All these results
suggest that NET1 and IPO7 are likely to be the real
targets of miR-22. We have carried out further experi-
ments with NET1 as it is a RhoA specific guanine
nucleotide exchange factor [25] and has been reported
to be involved in pathways associated with actin cyto-
skeletal rearrangement, trans-endothelial migration of
leucocytes, vascular endothelial growth factor signaling
and pancreatic cancer (Fig. 2D) [26]. Further, we
estimated the expression level of NET1 by qRT-PCR
in PBMCs of CML patients (patient subset 14–30).
The results showed that the level of NET1 was signifi-
cantly higher in all the patients compared with that of
the control cells validating the results obtained using
cell lines (Fig. 2E). NET1 and miR-22 levels show an
inverse correlation as expected if NET1 is one of the
targets of miR-22. Analysis of expression data
obtained from GEO suggested that the expression of
NET1 is positively associated with many cancers, such
as CML (GDS2342), prostate cancer (GDS1439), pap-
illary thyroid carcinoma (GDS1732) and breast cancer
(GDS1250). Furthermore, our analysis also showed
that NET1 is expressed at a higher level in other mye-
loid leukemia cell lines, such as THP-1, KG-1 and
U937 (GDS2251). In addition, we noticed that the
level of NET1 is high in relapse cases in comparison
with those where there is complete remission
(GDS1059) (Fig. 3).
Further validation of NET1 as a target of miR-22
was done by using 30-UTR reporter gene assay. Lucif-
erase was used as a reporter and was cloned upstream
of the 30-UTR of NET1 so that luciferase level was
controlled by miR-22. TARGETSCAN was used to identify
the miR-22 binding site in NET1 30-UTR (Fig. 4A).
Mutant NET1 30-UTR luciferase construct was gener-
ated where a mutation (three nucleotides at the fourth
to sixth positions) was introduced at the miR-22 bind-
ing site, specifically in the seed binding region. While
the level of luciferase decreased on overexpression of
miR-22 when wild-type 30-UTR was used, there was
no significant change in luciferase expression when
miR-22 was overexpressed in cells carrying mutant
30-UTR luciferase construct (Fig. 4B). Similar observa-
tions were made when NET1 protein level was
determined using western blotting. Overexpression of
miR-22 decreased the level of NET1 (Fig. 4C)
(Fig. 4D displays the expression level of transfected
miR-22). We checked the specificity of interaction of
miR-22 with NET1 by using full-length mutant NET1
carrying three altered nucleotides in the miRNA bind-
ing region. miR-22 was expressed in cells carrying
mutant NET1. There was no effect of ectopically
expressed miR-22 on mutant NET1 as no significant
change in the level of NET1 was observed (Fig. 4E).
The expression level of ectopically expressed miR-22 is
also shown in Fig. 4F.
Single-nucleotide polymorphisms (SNPs) often mod-
ulate activities of genes, thereby regulating cellular
physiology including tumorigenesis [27]. Therefore we
searched for the presence of SNPs in 30-UTR of
NET1, particularly in the miR-22 recognition site, in
order to identify genetic determinants that regulate
miR-22 and NET1 interaction. The dbSNP was
searched and 31 SNPs were found in the 30-UTR of
NET1. Amongst these, rs184456571 was mapped to
the seed sequence of miR-22 binding site. In order to
test if this SNP may have a physiological role we cre-
ated a mutant NET1 30-UTR containing the same
change and used the luciferase reporter system for
functional analysis. The results showed that the pres-
ence of this SNP is likely to generate an miR-22 insen-
sitive form of NET1 (Fig. 4G). All these results
suggest that NET1 is a validated target of miR-22 and
that this SNP may have a role in regulating miR-22
mediated control of NET1 expression.
It has been mentioned that PMA differentiates
K562 cells into megakaryocytes and consequently
enhances the level of miR-22 in PMA-treated cells
(Fig. 4H). Therefore it is expected that the NET1 level
should go down after PMA treatment. Western blot
analysis showed that the level of NET1 decreased sig-
nificantly after treatment with PMA correlating with
the increased expression of miR-22 (Fig. 4I). All these
results strongly suggest that NET1 is one of the bio-
logically relevant targets of miR-22.
Table 1. Predicted target genes of miR-22.
ARHGEF
CPEB1
WASF1
NET1
YARS
MTHFR
IPO7
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Analysis of miRNA and mRNA transcriptome of
K562 cells treated with PMA
PMA-treated K562 cells differentiate into megakaryo-
cytes and these treated cells are quite often used as a
model for normal cells [28]. In order to find similarities
in miRNA expression pattern between normal PBMCs
and PMA-treated K562 cells we analyzed both miR-
NA as well as mRNA transcriptome of K562 cells
with and without treatment with PMA. These results
were compared with the results obtained when PBMCs
from normal individuals were compared with K562.
For miRNA transcriptome we carried out next genera-
tion sequencing of small RNAs and analyzed the
results as described in our previous publication [10].
Expression of six miRNAs was found to follow the
same pattern when either normal PBMCs or PMA-
treated K562 cells were compared with untreated K562
cells (Table 2). Similarly we have looked at expression
of putative targets of miR-22 and identified common
differentially expressed target genes in K562 cells with
or without PMA treatment and K562 cells relative to
normal PBMCs. Targets which show inverse correla-
tion with miR-22 upon PMA treatment (NET1,
YARS, IPO7, WASF1 and CPEB1) were also
observed in a K562/normal PBMC combination
(Table 3). The results show that PMA-treated K562
cells partially behave like normal PBMCs and
strengthen our earlier observation that NET1 is likely
to be a major target of miR-22.
miR-22 is involved in cell growth and
proliferation
NET1 has been suggested to be involved in prolifera-
tion and differentiation of myeloid cells [29]. Therefore
we investigated the involvement of miR-22 in cellular
proliferation. Upon overexpression of miR-22, the
growth rate of K562 cells decreased by 50% compared
with cells carrying a scramble control plasmid
(Fig. 5A). When NET1 expression was downregulated
by specific small interfering RNA (siRNA) in K562
cells, there was a decrease in cell proliferation by 43%.
Correspondingly cell numbers increased by 42% on
A
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Fig. 3. GEO data analysis of NET1 expression in other cancers. (A) GDS2342: analysis of CD34+ hematopoietic stem and progenitor cells
from the bone marrow of untreated patients with CML in the first chronic phase. (B) GDS1439: expression level of NET1 in prostate cancer
tumors that are benign, clinically localized, or metastatic and refractory to hormones. (C) GDS1250: comparison of atypical ductal
hyperplasia (ADH) tissues from patients with and without a history of breast cancer. (D) GDS2251: comparison of myeloid leukemia cells
with normal monocytes. (E) GDS911: expression level of NET1 in T98G cancer cells in growth arrest induced by 3 days of either serum
deprivation or contact inhibition. (F) GDS1059: analysis of mononuclear cells from chemotherapy treated patients of <15 years of age with
acute myeloid leukemia.
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overexpression of NET1 (Fig. 5A). We also carried
out a soft agar colony formation assay to assess the
regulatory effect of transiently expressed miR-22 in
K562 cells. We found that either overexpression of
miR-22 or downregulation of NET1 expression by siR-
NA decreased drastically the number of K562 colonies
(Fig. 5B). On the other hand overexpression of NET1
further enhanced colony formation (Fig. 5B). Colonies
were counted with a Nikon SM2 1500 microscope.
There was an approximately 0.50-fold decrease in the
number of colonies in miR-22 overexpressing K562
cells (Fig. 5D). There was an increase in the number
of colonies by more than 2-fold in NET1 overexpres-
sed K562 cells (Fig. 5E) and a decrease of more than
0.30-fold in NET1 knocked down cells (Fig. 5F). The
size of the colonies was also reduced in the case of
miR-22 overexpression (average size of colonies
became half, 60 257 lm2 versus 136 773 lm2,
A
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Fig. 4. miR-22 targets NET1. (A) Schematic representation of NET1 30-UTR. It has one miR-22 binding site at the 50 end. (B) Luciferase
activity of constructs carrying wild-type and mutated NET1 30-UTR in miR-22 overexpressing K562 cells. Mutation was carried out in the
miR-22 complementary site. (C) Western blot of NET1 in miR-22 overexpressing K562 cells. (D) Graph represents the expression level of
miR-22 in miR-22 overexpressed K562 cells. (E) Western blot of NET1 in K562 cells stably overexpressing mutated NET1 gene. The
mutation was in the miR-22 binding site in the 30-UTR. Mutant form of NET1 was transfected in K562 cells with or without miR-22. (F)
Graph represents the expression level of miR-22. (G) The SNP (ID rs184456571) that maps to the miR-22 binding site of NET1 30-UTR was
identified by searching the dbSNP. Luciferase assay was carried out in cells carrying luciferase NET1 30-UTR construct with or without miR-
22 expressing plasmid. NET1 30-UTR used here carried the SNP indicated above. (H) Expression level of miR-22 in PMA-treated K562 cells.
(I) NET1 levels in K562 cells treated with 20 nM PMA were determined by western blot using IgG NET1 antibody. From (B) to (F) the
controls were scrambled RNA expressing cells. Graphical data points denote mean  SD (t test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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P ≤ 0.005) and NET1 knockdown (decreased by 0.63-
fold, 35 430 lm2 versus 55 584 lm2, P ≤ 0.005) as
analyzed by NIS ELEMENTS AR 4.0 software. In NET1
overexpressed K562 cells, the size of the colonies
increased significantly (3-fold, 81 464 lm2 versus
27 270 lm2, P ≤ 0.005). When mutant NET1
(DNET1) was overexpressed there was no significant
change in colony-forming units irrespective of whether
miR-22 was overexpressed or not (Fig. 5C). Figure 5G
shows the NET1 protein level in miR-22/NET1
overexpression and NET1 knockdown experiments.
Figure 5H,I shows the expression level of ectopically
expressed miR-22 in K562 cells used for the soft agar
colony formation assay. Inhibition of proliferation was
further analyzed to check if there is a block at a spe-
cific point in the cell cycle of K562 cells. There was a
significant decrease (12.15%, *P ≤ 0.013) at the G2/M
phase of the cell cycle in cells overexpressing miR-22.
A significant proportion of cells were arrested in the
G1 (3.5%) and S phases (7%, *P ≤ 0.044) (Fig. 5J).
We also carried out cell cycle analysis after downregu-
lation of NET1 expression with siRNA. The results
were similar to that seen on overexpression of miR-22.
After knockdown of NET1 there was a decrease of
10.28% (**P ≤ 0.0035) at the G2/M phase with a con-
comitant increase of 11.50% (***P ≤ 0.0008) in the
G1 phase (Fig. 5K). On the other hand overexpression
of NET1 increased the G2/M population of cells (8%,
*P ≤ 0.019) (Fig. 5L). In order to check whether the
results may be due to decreased proliferation or cell
death due to apoptosis, we performed 5-bromo-2-de-
oxyuridine (BrdU) incorporation assay in miR-22
overexpressed K562 cells. There was a 40% decrease
in incorporation of BrdU in miR-22 overexpressed
K562 cells suggesting that the decrease in the number
of cells is indeed due to decreased proliferation of
K562 cells (Fig. 5M). We can conclude from these
results that miR-22 inhibits proliferation of K562 cells
and this effect is probably due to targeting of NET1
by miR-22.
Effect of miR-22 on actin fiber formation
NET1 is known to modulate actin fiber formation as
it regulates RhoA, a regulator of actin dynamics [30].
Therefore we checked the effect of ectopically
expressed miR-22 on actin fiber formation. Over-
expression of miR-22 in K562 cells decreased actin
fiber formation as was evident from confocal micros-
copy images (Fig. 6A). The staining pattern was simi-
lar to that of cells where NET1 expression was
downregulated with specific siRNA. The results
Table 2. miRNAs displaying a similar expression pattern in normal
PBMCs and PMA-differentiated K562 cells.
miRNA
Normal PBMCs/K562
cells (fold change)
PMA-treated K562/control
K562 (fold change)
hsa-mir-146b 5.7057 2.3311074
hsa-mir-22 4.6518 2.0415248
hsa-mir-24 12.1140 3.7387884
hsa-mir-27a 11.802 2.9122117
hsa-mir-486 0.4135 0.3168723
hsa-mir-504 0.1125 0.3680543
Table 3. Expression of miR22 targets in PMA-treated K562 cells as
deduced from microarray expression analysis.
Target genes of miR-22 Fold change (log2)
YARS 1.64
NET1 0.52
IPO7 0.98
MTHFR 0.53
WASF1 0.20
CPEB1 0.42
ARHGEF12 0.01
Fig. 5. Effect of miR-22 on growth and proliferation of K562 cells. (A) Proliferation was determined by measuring the number of cells at
indicated times in cells stably expressing precursor miR-22 gene, NET1 and transiently expressed siNET1. The controls were scrambled
RNA expressing cells. (B) Soft agar colony formation assay was also used as a measure of proliferation. It was carried out with K562 cells
transiently expressing miR-22, NET1 or siRNA against NET1. The controls were scrambled RNA expressing cells. Colonies were counted on
the 14th day. (C) Colony-forming units of cells overexpressing mutant NET1 (lacking miR-22 binding site) with or without overexpressed
miR-22. Colonies were counted on the 14th day. The control was scrambled RNA expressing cells. (D–F) Graphs represent number of
colonies in soft agar assay counted with the help of Nikon NIS ELEMENTS AR 4.0. (G) Western blots to show the level of NET1 in miR-22/NET1
overexpressed and NET1 knocked down cells using siRNA. (H–I) Graphs represent expression level of miR-22 in miR-22 overexpressed
K562 cells used in the soft agar colony formation assay. Cell cycle analysis was carried out for indicated cells using flow cytometry after
propidium iodide labeling following standard methods. (J) K562 cells overexpressing miR-22. (K) K562 cells transfected with siNET1. (L)
K562 cells overexpressing NET1. All experiments were carried out three times. (M) BrdU uptake assay was performed to assess
proliferation of stable miR-22 overexpressed K562 cells. Absorbance represents the extent of BrdU incorporated during the S phase of the
cell cycle. Decrease in absorbance in miR-22 overexpressed cells suggests a decrease in proliferation of K562 cells. Graphical data points
denote mean  SD (t test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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suggest that miR-22 may be regulating proliferation of
cells by controlling actin dynamics. An intensity profile
plot was generated on the basis of the intensity of
actin fibers formed in the cytoplasm by IMAGEJ soft-
ware using phalloidin. This was done by quantitatively
analyzing the difference in actin fiber formation by
A
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taking the average of 15 randomly selected cells from
each experiment (miR-22 overexpressed, siNET1 and
NET1 overexpressed cells) (Fig. 6B) [31]. The results
showed that NET1 overexpression results in an increased
amount of actin fiber formation. On the other hand the
levels of actin fiber decreased on decreasing either
NET1 expression or miR-22 overexpression (Fig. 6B).
In order to investigate whether the effect of miR-22
on NET1 expression is cell specific we have studied the
effect of miR-22 on the proliferation of HL60 cells.
These cells are derived from a patient with acute
myeloid leukemia [32]. We had shown earlier that
miR-22 is downregulated in HL60 cells [10]. We
validated the low expression level of miR-22 in HL60
cells relative to that of normal PBMCs by qRT-PCR
(Fig. 7A). When we overexpressed miR-22 in
HL60 cells expression of NET1 decreased by 47%
(Fig. 7B). miR-22 overexpressed HL60 cells displayed
A
B
Fig. 6. Imaging of actin cytoskeleton in
K562 cells. (A) Indicated cells were fixed
and stained with phalloidin-TRITC before
viewing under a confocal microscope
(Olympus Fluoview FV1000). miR-22 and
NET1 were transiently expressed in K562
cells. Imaging was also done with K562
cells containing siRNA against NET1 that
resulted in low expression of NET1. (B)
Intensity profiles represent the
fluorescence intensity of actin stress
fibers of the corresponding image. Graph
represents the fluorescence intensity of
actin in miR-22, NET1 and siRNA-NET1
transfected K562 cells. Data shown in the
graph are an average of 15 randomly
selected cells. Controls were scrambled
RNA expressing cells. Graphical data
points denote mean  SEM. (t test,
***P < 0.001)
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a reduction in proliferation by 50%. Moreover, NET1
knockdown and NET1 overexpressed HL60 cells also
showed altered proliferative ability, a reduction in
growth by 35% and an increase in cellular prolifera-
tion by 45% respectively (Fig. 7C). We further per-
formed soft agar colony formation assay to confirm
the growth inhibitory effect of miR-22 in HL60 cells
(Fig. 7D). miR-22 overexpressed cells exhibited a
0.25-fold decrease in colony number while NET1
knockdown and NET1 overexpressed HL60 cells
showed a 0.75-fold decrease and a 2-fold increase in
the number of colonies respectively (Fig. 7E,F,G). We
also measured the size of the colonies. In the case of
miR-22 overexpression, the colony size decreased
(75 195 lm2 versus 490 100 lm2, P ≤ 0.0005). In the
case of NET1 knockdown the size of the colonies
decreased (82 124 lm2 versus 156 668 lm2, P ≤ 0.005)
whereas there was an increase in colony size in NET1
overexpressed cells (485 527 lm2 versus 136 162 lm2,
P ≤ 0.005). Figure 7H shows the expression level of
miR-22 in miR-22 overexpressed cells. Figure 7I shows
the expression level of NET1 in miR-22 overexpressed,
NET1 knockdown and NET1 overexpressed cells used
in the soft agar colony formation assay. These results
suggest that downregulation of miR-22 is an attribute
of myeloid leukemia and is required for its regulated
proliferation.
Discussion
miRNAs control gene expression at the post-transcrip-
tional level, thereby bringing in an additional layer of
control in gene regulation. Therefore, it is expected
that any change in miRNA levels may result in altera-
tions of the cellular state through regulation of gene
networks resulting in initiation of the disease process
[33]. A number of studies have already shown a link-
age between altered levels of miRNAs and many
diseases (for a recent review see [34]). Consequently it
is not surprising that miRNAs may also be involved in
the transition from normal to CML cells. We have
shown earlier that there is a defect in miRNA synthe-
A
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Fig. 7. Effect of miR-22 on proliferation of HL60 cells. (A) Graph represents the expression level of miR-22 in HL60 cells relative to PBMCs
of two normal volunteers. (B) Expression level of NET1 in HL60 cells transiently overexpressing miR-22. (C) Proliferation was determined by
measuring the number of HL60 cells that transiently overexpressed miR-22, NET and siRNA-NET1. The controls were scrambled RNA
expressing cells. Cells were counted after 48 h. (D) Soft agar colony formation assay was carried out with HL60 cells transiently expressing
miR-22, NET1 or siRNA against NET1. The controls were scrambled RNA expressing cells. Colonies were counted on the 14th day. (E–G)
Graphs represent number of colonies in soft agar assays counted with the help of Nikon NIS ELEMENTS AR 4.0. (H) The graph represents the
expression level of miR-22 in miR-22 overexpressed HL60 cells. Control cells were scrambled RNA expressing cells. (I) Western blot to
show the level of NET1 in miR-22/NET1 overexpressed and NET1 knocked down cells. Graphical data points denote mean  SD (t test,
*P ≤ 0.05, **P ≤ 0.01).
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sis in the CML cell line K562 but not in the acute
myeloid leukemia cell line HL60 [10]. Levels of a num-
ber of miRNAs were found to be significantly less in
K562 cells compared with normal PBMCs. A number
of miRNAs were also found to be downregulated in
HL60 cells. In order to explore the relationship
between low levels of some of the miRNAs and leuke-
mia, we selected for further studies some of the low
expressing miRNAs that are already suspected of par-
ticipation in cancer. Estimation of expression level in
30 CML patient cells showed miR-22 to be the major
downregulated miRNA among a few other miRNAs
that were studied (miR-27a and miR-324-5p; these two
miRNAs were studied in patient subset 1–5). This
result along with the observations that overexpression
of miR-22 altered the growth and proliferative prop-
erty of K562 cells and that miR-22 levels increase on
differentiation of these cells strongly indicated that it
may be involved in leukemia genesis.
The results presented here clearly show that miR-22
mediates its biological function by targeting NET1.
There are a number of reports that show that NET1 is
a target of miR-22. For example, the complementary
sequence of miR-22 is present in the 30-UTR of NET1,
expression of a reporter construct with NET1 30-UTR
is under the control of miR-22 levels and mutation of
the complementary miR-22 recognition site abolishes
this control by miR-22. Moreover, NET1 and miR-22
levels were inversely correlated when K562 cells were
differentiated with PMA. NET1 has already been
shown to be associated with cancer. It is known to be
overexpressed in many malignancies and regulates inva-
sion of cancerous cells [35,36]. However, the results pre-
sented here strongly indicate that NET1 is the main
target that mediates the involvement of miR-22 in leu-
kemia. We have observed that downregulation of
NET1 gives the same phenotype as that seen on overex-
pression of miR-22 including reduction in the forma-
tion of actin fibers. Since NET1 is a regulator of RhoA
that controls actin dynamics our results clearly indicate
that some of the functions of miR-22 are mediated
through NET1. miRNAs play a crucial role in regula-
tion of NET1 expression during tumorigenesis as is evi-
dent by the finding that its expression is modulated by
another miRNA miR-24 during epithelial to mesenchy-
mal transition [37]. We also found that miR-24 is down-
regulated in K562 cells which suggests that regulation
of NET1 expression in K562 cells may be the cumula-
tive effect of miR-22 and miR-24. This is not surprising
as it is known that on the one hand a number of miR-
NAs can target a single gene and on the other hand a
single miRNA can target multiple genes [38]. Therefore
miR-22 and NET1 along with other genes and
miRNAs, such as miR-24, can form an intricate regula-
tory system, a perturbation of which can lead to tumor
formation. Since miR-22 is likely to have other targets,
it is possible that other targets may also be involved in
mediating some of the functions of miR-22, e.g. miR-22
regulates Max expression and inhibits cell cycle pro-
gression in HL60 cells [11]. Recently, it has been
reported that expression of miR-22 gets upregulated in
myelo-dysplastic syndrome (MDS) [39]. In MDS miR-
22 decreases the expression of its target gene TET2 that
results in initiation and progression of MDS [39]. In
our study, we found that TET2 expression is downregu-
lated in the K562 (2.5-fold) and HL60 (0.8-fold) cell
lines although the expression of miR-22 is also down-
regulated which suggests that other factors may be
involved in the downregulation of TET2 in these cell
lines. Our observation regarding the presence of an
SNP in the miR-22 binding site of NET1 is intriguing.
Although this SNP is thought to be rare, it appears to
have a drastic effect in miR-22 regulation through
NET1. At present we do not know the frequency of this
SNP in the population nor do we have any idea of its
biological role. However, we feel that a detailed analy-
sis of the population may throw light on the importance
of this SNP. In conclusion, we suggest that downregula-
tion of miR-22 levels may have a crucial role in leuke-
mia genesis and the transition to cancer cells may be
partly mediated through NET1.
Materials and methods
Cell culture and reagents
K562 cell line was obtained from the National Centre for
Cell Sciences, Pune, India and maintained in RPMI 1640
(Life Technologies, USA, cat no. 11875–119). The medium
was supplemented with 10% fetal bovine serum (Life Tech-
nologies, USA, cat no 10082147) and penicillin–streptomy-
cin and maintained at 37 °C with 5% CO2 in an incubator
chamber. HL60 cell line was a generous gift from S. Gopa-
lan Sampathkumar, National Institute of Immunology,
New Delhi, India. HL60 cells were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum.
PBMCs were obtained at the time of diagnosis from
patients with CML after signed informed consent had been
obtained from the patient in accordance with the Declara-
tion of Helsinki. This study was approved by the hospital
(AIIMS, New Delhi, India) according to the guidelines of
the hospital’s ethics committee (reference no. A-36:20/10/04).
PMA (Sigma, USA, cat. no. P1585) treatment was given
to K562 cells at a concentration of 20 nM. siNET1 (cat.
no. 4392420, id: s20077) was purchased from Ambion,
USA.
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Cell separation
Myeloid cells were separated using Miltenyi Biotec
magnetic cell sorting micro-beads with IgG CD33 antibody
according to the manufacturer’s protocol (cat. no. 130-045-
501). Briefly, PBMCs were isolated by Histopaque (cat. no.
10771; Sigma) and approximately 107 cells were incubated
with 20 lL IgG CD33 antibody conjugated with magnetic
beads for 20 min. Cells were washed and passed through
the column attached to a magnet. Cells were washed thrice
and finally eluted. The purity of the separated cells was
confirmed by staining them with FITC-CD13 antibody
(cat. no. MHCD1301; Life Technologies) and analyzing by
flow cytometry (FACSCalibur; BD).
RNA isolation and real-time PCR
Total RNA isolation was carried out from peripheral blood
and K562 cells using TRIzol Reagent (Invitrogen) as per
the manufacturer’s instruction. DNase 1 treatment was given
to the total RNA as per the supplier’s instruction (Invitro-
gen). Total RNA was used for cDNA synthesis using Super-
scriptIII (Invitrogen). This cDNA was used for real-time
PCR of miRNA target genes with SYBR Green chemistry
(Applied Biosystems). Real-time PCR for miRNAs was
performed with TaqMan miRNA assays according to the
manufacturer’s protocol (Applied Biosystems). Primers used
for RT-PCR are as follows: F NET1, 50-TGGTCACATTC
TCGTGAGCTGGTTAC-30; R NET1, 50-CAATATAGC
ATCCTCCAGAAGCTGAACATC-30; F YARS, 50-CCAG
CTCAGCAAAGAGTACACACTAGATG-30; R YARS, 50-
AATACTCTTCATCCAAAGCCTGCAGTC-30; F MTHFR,
50-CCGCTGGGGCAATTCCTCTTC- 30; R MTHFR, 50-CA
GGCAAGTCACTTTGTGACCATTCC-30; F IPO7, 50-CA
GCTCAATGAAGCACACAAGTCTCTG-30; R IPO7, 50-TG
AATGCATGTAGTAAGCTGTACCCTGATG-30; F GAP-
DH, 50-GGTCGGAGTCAACGGATTTGGTC-30; R GAP-
DH, 50-GAGGGATCTCGCTCCTGGAAG-30; F CPEB1,
50-GAGCAGCACACACTCGGTACTGAG-30; R CPEB1,
50-GCGAAGGCTTGAAATCAAATCTGAG-30; F ARHGE-
F12, 50-CACAGGCTCTGCTCAGGATGGA-30; R ARHG-
EF12, 50-GGGCCACTCTTGGGACTATCTGC-30; F
WASF1, 50-GAAGGAAAAGAGGAAGCAGAAGCA
G-30; R WASF1, 50-CCACGTATGTCTGAGGTCTTGTT
TC-30.
Northern blotting
We did northern blotting for mature miRNA detection in
PMA-treated K562 cells. The protocol used is a modification
of the conventional northern blot developed by Pall et al.
[40]. Here a chemical crosslinker, 1-ethyl-3-(3-dimethylami-
nopropyl) carbodiimide (EDC) (cat. no. E7750) is used
instead of UV crosslinking. Briefly, 20 lg of total RNA was
run on 15% denaturing urea PAGE. RNA was transferred
to a nylon membrane and crosslinked by EDC for 1 h at
65 °C. The blot was probed with cP32-end labeled antisense
probe of miR-22 overnight at 42 °C. After washing, the blot
was visualized using a Phosphorimager. The sequences of
the antisense DNA probes for miR-22 and RNU6A were
50-ACAGTTCTTCAACTGGCAGCTT-30 and 50-AATATG
GAACGCTTCACGAATTTG-30 respectively.
miRNA target prediction
The potential targets of the differentially regulated
miRNAs were predicted using the following criteria. We
used the online tool MIRECORDS for target prediction which
uses an array of many target prediction programs
(DIANA-MICROT, MICROINSPECTOR, MIRANDA, MIRTARGET2,
MITARGET, NBMIRTAR, PICTAR, PITA, RNA22, RNAHYBRID and
TARGETSCAN/TARGERTSCANS) [41]. We considered only those
targets which were predicted by at least five programs. Then
we compared these predicted targets with genes which were
upregulated in K562 microarray data as we know miR-22 is
downregulated in K562. Genes common in the prediction
list and microarray data were selected as potential target
candidates and were confirmed by experimental methods.
Western blotting
Total cell lysate was prepared in RIPA buffer. 50 lg of
total cell lysate was used for western blotting. The lysate
was run on SDS/PAGE and then transferred on a poly
(vinylidene difluoride) membrane (Millipore, USA). The
membrane was blocked in 5% BSA. The antibody for
NET1 (cat. no. H00010276-B01) was purchased from
Abnova and used according to the manufacturer’s protocol.
For loading control, we used b-actin/b-tubulin antibodies
(BD Biosciences). Densitometry analysis was done using
ALPHAIMAGER software.
Cloning and transfection
miR-22 was cloned in pBabe-puro vector by cloning a
DNA fragment containing a sequence of miR-22 and its
flanking region to make stable cell lines. 30-UTR of NET1
was cloned downstream of the luciferase gene in
pMIR-Report vector. Primers used for cloning were F
NET1 50-ATAGAGCTCGCTCTGTGTGTTAACTGATG
GGAG-30, R NET1 50-ATAAAGCTTTATAATCGGGC
TTTTACTCCTCCTC-30. Mutant NET1 30-UTR was gen-
erated by site directed mutagenesis. Primers used for
mutagenesis were F NET1-mut 50-GTTCTTTTTTCTTT
TTTTAATGGGTCCTAAAGATATACAGATTACTG-30,
R NET1-mut 50-CAGTAATCTGTATATCTTTAGGACC
CATTAAAAAAAGAAAAAAGAAC-30. Primers used for
creating the SNP mutation in NET1 30-UTR were F
NET1-SNP 50-GTTCTTTTTTCTTTTTTTAATGGCTGC
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TAAAGATATACAGATTACTG-30, R NET1-SNP 50-AG
TAATCTGTATATCTTTAGCAGCCATTAAAAAAAGA
AAAAAGAAC-30. Transfection of plasmids was done with
Superfect (Qiagen). Transfection of pre-miR oligos was
done with siPORT NeoFX transfection reagent (Ambion).
Pre-miR-22 was used at a concentration of 30 nM. Trans-
fection of siRNA was done with RNAiMax transfection
reagent (Invitrogen) at a concentration of 10 nM.
Luciferase assay
Luciferase assay was performed with Dual Luciferase Assay
Kit (Promega). For normalization we used PRL-TK vector.
Cells were transfected with 30-UTR containing luciferase
vector in K562 cells with or without miR-22 and assayed
after 48 h.
Growth assay
Growth assay was done with miR-22 overexpressing cell
line. Cells were seeded in equal numbers for scramble vec-
tor control and miR-22 cell lines. Cells were manually
counted after 24 and 48 h respectively.
Soft agar colony formation assay
Cells were transiently transfected with miR-22/NET1/
siNET1 and then mixed with medium containing 0.70%
agar (final concentration 0.35%) and poured on 1% base
agar. Cells were allowed to grow for 10–15 days. Medium
was changed every day. On the final day, cells were stained
with 0.1% crystal violet and visualized under a Nikon SM2
1500 microscope. Further analysis of colony counting and
colony size measurement was done with the help of NIS ELE-
MENTS AR 4.0 software.
Cell cycle analysis
Cell cycle analysis was done with propidium iodide stain-
ing. Briefly, cells were fixed in cold ethanol in 4 °C for 2 h.
Then RNase treatment was given for 2 h by adding RNase
at a final concentration of 250 lgmL1. After that propidi-
um iodide was added at a final concentration of
50 lgmL1 for 20 min and cells were analyzed on a BD
FACSCalibur instrument.
BrdU incorporation assay
BrdU incorporation assay was performed with BrdU cell pro-
liferation assay kit (cat. no. 6813; Cell Signaling Technology)
according to the manufacturer’s protocol. Briefly, 4000 cells
were plated in a 96-well plate. BrdU (20 lM) was added to the
cells and these were incubated overnight at 37 °C. Cells were
collected by centrifugation and were then treated with fixing/
denaturing solution for 30 min before incubating with BrdU
detection antibody for 1 h. Cells were incubated with horse-
radish peroxidase conjugated secondary antibody after wash-
ing for 30 min. The bound antibodies were then detected by
incubating with TMB (3,30,5,50 TETRAMETHYLBENZI-
DINE) substrate for 30 min and the amount of color was
determined at 450 nm using a plate reader.
Confocal microscopy
Cells were transiently transfected with miR-22/NET1/
siNET1 and grown for 48 h. Cells were then transferred to
a poly L-lysine treated coverslip for 1 h, washed with
NaCl/Pi and fixed with 3.7% paraformaldehyde for 30 min
and washed again with NaCl/Pi. BSA (1% w/v) in NaCl/Pi
was used for blocking for 1 h; they were then stained with
TRITC conjugated phalloidin for 30 min and washed with
NaCl/Pi. Stained cells were mounted on a slide with
DABCO and visualized using Olympus Fluoview FV1000
laser scanning microscope. An intensity profile plot was
generated using IMAGEJ software [31].
Microarray analysis
Total RNA from normal PBMCs and K562 was used for
microarray expression profiling as stated in our previous
study and submitted in the GEO [10]. Microarray experi-
ments were done with one normal PBMC sample and one
K562 sample. The microarray for PMA-treated K562 was
done on an Agilent platform (GEO accession no.
GSE57734). Cells were treated with 20 nM PMA for 48 h
and sent for microarray to Genotypic Technology, Banga-
lore. Analysis was done by GENESPRING GX version 12.0 soft-
ware. The microarray of PMA-treated K562 cells was done
with one control and one PMA-treated K562 cell sample.
miRNA transcriptome analysis
The miRNA expression profile was generated from next
generation sequencing data as mentioned in our previous
publication [42]. Briefly, reads from both samples were
aligned to reference pre-miRNAs from miRBase release 20
and an expression profile of all isomirs was generated. All
the isomirs were clustered by using specifically developed
PERL script to give a complete expression profile.
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